Christoph Nowak
Directeur Technique/Scientifique/R&D chez DIAMYD MEDICAL AB
Fortune : 581 $ au 30/04/2024
Postes actifs de Christoph Nowak
Sociétés | Poste | Début | Fin |
---|---|---|---|
DIAMYD MEDICAL AB | Directeur Technique/Scientifique/R&D | - | - |
ONCOZENGE AB | Directeur/Membre du Conseil | 09/09/2023 | - |
Independent Dir/Board Member | 09/09/2023 | - | |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Christoph Nowak
Anciens postes connus de Christoph Nowak
Sociétés | Poste | Début | Fin |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - | - |
Formation de Christoph Nowak
University of Uppsala | Doctorate Degree |
University of Oxford | Doctorate Degree |
Technische Universität Braunschweig | Graduate Degree |
Statistiques
Internationale
Suède | 6 |
Royaume-Uni | 2 |
Allemagne | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 2 |
Graduate Degree | 1 |
Sectorielle
Consumer Services | 5 |
Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
DIAMYD MEDICAL AB | Health Technology |
ONCOZENGE AB | Health Technology |
Entreprise privées | 1 |
---|---|
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Health Technology |
- Bourse
- Insiders
- Christoph Nowak
- Expérience